after joining the study you sign a consent form that explains the purpose, procedures, possible benefits and risks of the trial.

the study team records your medical history, performs physical examinations, takes blood samples, and obtains imaging studies to document the extent of the low grade upper tract urothelial carcinoma.

a tissue test is done to confirm the presence of an FGFR3 alteration, which is required for participation.

you begin taking dabogratinib (identified as tyra-300-b01) in tablet form.

each tablet contains 99 mg of the active substance and is taken by oral use according to the schedule given by the investigator.

you attend clinic visits approximately every four weeks.

during each visit blood tests are repeated and any side effects, also called adverse events, are recorded.

imaging studies are performed at 6 months, 12 months and 24 months after the first dose to assess tumour response.

the primary goal is to determine the complete response rate, which means disappearance of all detectable cancer.

the investigator decides whether you continue the medication based on safety results and tumour response.

treatment may be stopped if disease progresses, unacceptable side effects occur, or the predefined treatment period ends.

after stopping the study drug you continue to be monitored for safety and disease status at scheduled intervals.

follow‑up visits include physical examinations, blood tests and imaging as required to document long‑term outcomes.